Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis

Kidney Int Rep. 2023 Feb 3;8(4):925-928. doi: 10.1016/j.ekir.2023.01.034. eCollection 2023 Apr.

Go Anan^{1

2}, Daisuke Kikuchi³, Takuo Hirose^{4

5

6}, Hiroki Ito⁴, Shingo Nakayama⁴, Takefumi Mori^{4

5}

¹ Department of Urology, Yotsuya Medical Cube, Tokyo, Japan.
² Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan.
³ Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
⁴ Division of Nephrology and Endocrinology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
⁵ Division of Integrative Renal Replacement Therapy, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
⁶ Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine, Sendai, Japan.

No abstract available

Keywords: diabetes; epidemiologic study; inflammation; metabolic syndrome; sodium-glucose cotransporter-2 inhibitor; urolithiasis.